Paquinimod

小分子

帕喹莫德

T0143 | DTXSID90179537 | ABR?215757 | BCP29381 | ABR25757 | ABR-25757 | C74280 | DB13118 | Paquinimod [INN] | SCHEMBL1573633 | N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide | DIKSYHCCYVYKRO-UHFFFAOYSA-N | EX-A2923 | ABR-215757 | 3-M

Paquinimod

P647576-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

Paquinimod (ABR 25757) is a specific and orally active inhibitor of S100A8/S100A9 . Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice In Vivo S100A9 is a calcium-binding protein of the S100 family. Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. Prophylactic treatment with S100A9 inhibitor Paquinimod reduces pathology in experimental collagenase-induced osteoarthritis . Paquinimod is a potent inhibitor of insulitis and diabetes development in the NOD mouse. To assess the preventive efficacy of Paquinimod on diabetes development in female NOD mice, groups of mice are treated with daily doses of 0.04, 0.2, 1, and 5 mg/kg/day of Paquinimod from week 10 of age until week 20 of age. Glycosuria is analyzed on a weekly basis from 10 weeks of age until the endpoint of the experiment at 40 weeks of age. There is a clear dose-dependent reduction in diabetes development in the Paquinimod-treated mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal administration Mice Female NOD/MrkTac mice are exposed to increasing concentration of CO 2 and upon loss of consciousness euthanized by cervical dislocation. To investigate the effect of the Q-compound Paquinimod on development of glycosuria and insulitis, mice are treated with Paquinimod dissolved in drinking water at different concentrations corresponding to daily doses of about 0.04, 0.2, 1, and 5 mg/kg body weight/day ). The mice are treated with Paquinimod starting from either 10 or 15 weeks of age. The duration of treatment varies from 5 to 23 weeks in the different experiments performed . aladdin has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:S100A9

Paquinimod（ABR 25757）是一种特异性口服活性 S100A8/S100A9 抑制剂。Paquinimod 可挽救 SARS-CoV-2 感染小鼠的肺炎，并显著降低病毒载量。

248282-01-1

C21H22N2O3

350.4 g/mol

607-446-0

54684617

CCC1=C2C(=CC=C1)N(C(=O)C(=C2O)C(=O)N(CC)C3=CC=CC=C3)C

N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide

1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3

DIKSYHCCYVYKRO-UHFFFAOYSA-N

CCC1=C2C(=CC=C1)N(C(=O)C(=C2O)C(=O)N(CC)C3=CC=CC=C3)C

54684617

248282-01-1

ABR-215757;paquinimod

DMSO : 62.5 mg/mL (178.36 mM; Need ultrasonic) H2O : <0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

1

3

4

350.163 Da

350.163 Da

60.900 Ų

26

0

580

0

1

3.8